Advertisement

Cervical Cancer

  • Nenad Markovic
  • Olivera Markovic
Chapter

Abstract

Cervical cancer remains the leading cause of cancer death in women across the globe. In the US, because of Pap test prevention, the number of women who die from cervical cancer has been drastically reduced. This is the best proof that prevention is exceedingly important to fight cervical cancer.

Keywords

Cervical Cancer Human Papilloma Virus Cervical Cancer Screening Sexually Transmitted Disease Invasive Cervical Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    ACCP. Cervical cancer prevention. Fact Sheet. 10 key findings and recom-mendations for effective cervical cancer screening and treatment programs. Cited Internet http://www.alliance-cxca.org/. Cited September 25, 2007
  2. 2.
    Agoff SN, Lin P, Morihara J et al (2003) p16INK4a expression correlates with degree of cervical neoplasia: a comparison with Ki-67 expression and detection of high-risk HPV types. Mod Pathol 16(7):665–673CrossRefPubMedGoogle Scholar
  3. 4.
    American Cancer Society Home. http://www.cancer.org. Cited September 17, 2007
  4. 5.
    American Cancer Society. Prevention & early detection. ACS guidelines for early detection of cancer. http://www.cancer.org/docroot/PED/content. Cited September 15, 2007
  5. 6.
    American Cancer Society Guidelines on nutrition and physical activity in cancer patients. http://caonline.amcancersociety.org. Cited August 17, 2007
  6. 7.
    Anonymous. Hysterectomy. Medical encyclopedia. http://www.answers.com/topic/hysterectomy. Cited June 30, 2007
  7. 8.
    Anonymous. Statistics about cervical cancer. WrongDiagnosis.com http://www.wrongdiagnosis.com/c/cervical_cancer/stats.html. Cited July 12, 2007
  8. 9.
    Anonymous. Chlamydial genital tract infections. Chlamydia as a cofactor in cervical cancer. http://www.chlamydiae.com/restricted/docs/infections/gentrac_cervical_cancer. Cited September 14, 2007
  9. 11.
    Anonymous. New biomarker for cervical cancer. Medical observer, December 1999. http://findarticles.com/articles/mi_m3230/is_12_31/ai. Cited July 4, 2007
  10. 12.
    Arrossi S, Sankaranayanan R, Parkin D. Incidence and mortality of cervical cancer in Latin America. IARC, WHO. http://www.scielosp.org/scielo.php?script=sci. Cited July 15, 2007
  11. 13.
    Arbyn M, Raifu AO, Autier P, et al (2007) Burden of cervical cancer in Europe: estimates for 2004. 2007 European Society for Medical Oncology. Ann Oncol online ISSN 1569–8041Google Scholar
  12. 14.
    ASCCP Practice recommendations. The cervix: histology. http://asccp.org/edu. Cited February 4, 2007
  13. 15.
    Austin R. Marshal. Information for ASC member posted on members list@cytopathology.org and ASCCP Home. http://www.asccp.org/consensus.shtml. Cited September 4, 2007
  14. 16.
    BBC News on April 9, 2007. Staining ‘spots cervical cancer’ http://news.bbc.co.uk/go/pr/fr/-/2/hi/health/6518685.stm. Cited August 28, 2007
  15. 18.
    Bioscreening Industry News. November 7, 2005. TriPath Imaging, Inc. (NASDAQ) PRNewswire-First Call. New research study provides further evidence of strong correlation of TriPath Imaging ProEx C Biomarkers with biopsy evidence of high-grade cervical intraepithelial neoplasia (CIN 2+)Google Scholar
  16. 19.
    Bibbo M (1997) Comprehensive cytopathology. W.B. Saunders, PhiladelphiaGoogle Scholar
  17. 20.
    BioSciCon’s electronic Survey. Web Site link. http://www.surveymk.com/s.aspx?sm=aKALIgzj7AwSthXcp0nI1w_3d_3d. Cited September 25, 2007
  18. 21.
    BioSciCon’s web portal: http://www.bioscicon.com
  19. 22.
    BioSciCon’ MarkPap Self test. http://bioscicon.com/productsindev.html
  20. 23.
    Biswas R. Rural Indian women face heightened cervical cancer risks. PRB Population Reference Bureau. http://www.prb.org/Articles/2004/RuralIndian. Cited June 8, 2007
  21. 24.
    Bischoff R, van der Greef J, van der Zee AGJ. Project: discovery of new biomarkers for cervical cancer. KNAW-Research Information. http://www.onderzoekinformatie.nl/en/oi/nod/onderzoek. Cited 10 August, 2007
  22. 26.
    Bokemeyer C, Hartmann JT, Kuczyk MA, et al (1996) The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tunics. World J Urol 14(6):354–359. Springer, Berlin. ISSN 0724–4983 and (online) 1433–8726Google Scholar
  23. 27.
    Bosch FX, Munoz N, de Sanjose S et al (1992) Risk factors for cervical cancer in Colombia and Spain. Int J Cancer 52(5):750–758CrossRefPubMedGoogle Scholar
  24. 28.
    Brake T, Connor JP, Petereit D, Lambert PF (2003) Comparative analysis of cervical cancer in women and in a human papillomavirus-transgenic mouse model. Cancer Res 63:8173–8180PubMedGoogle Scholar
  25. 29.
    Brinton LA (1992) Epidemiology of cervical cancer-overview. IARC Sci Publ 119:3–23Google Scholar
  26. 31.
    Cancer Research UK. Cervical cancer chemotherapy http://cancerhelp.org.uk/help/default.asp?page=2779. Cited September 9, 2007
  27. 32.
    CancerHelp UK (sponsored by NHS Direct Online). Which surgery for cervical cancer, from Internet http://www.cancerhelp.org.uk/help/default/asp?page=9188. Cited January 6, 2007
  28. 33.
    Cancer Centers of America. Complementary & alternative medicines for cervical cancer treatment. http://www.cancercenter.com/cervical-cancer/complementary. Cited July 17, 2007
  29. 34.
    Cancer Research UK. About cervical cancer radiotherapy. http://cancerhelp.org.uk/help. Cited July 7, 2007
  30. 35.
    Cancer Research UK. Cervical cancer chemotherapy. http://cancerhelp.org.uk/help/default.asp/page=2779. Cited September 19, 2007
  31. 36.
    CAP Advocacy Group. Guidelines for the review of Pap tests in the context of litigation or potential litigation. College of American Pathologists Policy Guidelines adopted February 1998, reaffirmed October 2005. http://www.cap.org/cap.portal?. Cited September 29, 2007
  32. 38.
    Castellisage X, Diaz M, de Danjose S et al (2006) Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactor: implications for screening and prevention. J Natl Cancer Inst 98(5):303–315CrossRefGoogle Scholar
  33. 40.
    Centers for Disease Control and Prevention. STD Surveillance. http://www.cdc.gov/std/stats/tables/table42.htm. Cited July 31, 2007
  34. 41.
    Centers for Disease Control and Prevention. Vaccines and immunization. HPV vaccination. http://www.cdc.gov/vaccines/vpd-vac. Cited July 25, 2007
  35. 42.
    Cervical cancer in Latin America and the Caribbean. PAHO (Pan American Health Organization), Regional Office of WHO (World Health Organization). PAHO, Fact Sheet 2001Google Scholar
  36. 43.
    CDC. DES Home. DES update: consumers. Potential health risks for DES daughters. http://www.cdc.gov/des/consumers. Cited June 27, 2007
  37. 44.
    CDC. MMWR (2007) QuickStats: prevalence of HPV infection among sexually active females aged 14–59 years, by age group. National Health and Nutrition Examination Survey, United States 2003–2004, MMWR weekly report 24 August 24, 2007/56(33):852Google Scholar
  38. 45.
    Cervical Cancer/HPV Community. Daily Newsletter Online. September 16, 2007. Post Conference Reports. Publisher National Cervical Cancer Coalition cervicalcancer@clinicahealth.com. Cited September 16, 2007Google Scholar
  39. 46.
    CNN.com. Health library. Diseases and conditions. Cervical cancer from Mayo clinical special to CNN. On June 22 2007. http://www.cnn.com/HEALTH/library/DS/00167.html. Cited July 12, 2007
  40. 47.
    Center for Disease Control and Prevention. AIDS/HIV multitude of pages for review available http://www.cdc/hiv.gov. Cited April 3, 2007
  41. 48.
    CLIA, Clinical Laboratory Improvement Amendments of 1988. See CDC web site http://cdc.gov/. Cited August 1, 2006
  42. 51.
    Cortez D, Glick G, Ellege SJ (2004) Minichromosome maintenance proteins are direct targets of the ATM and ATP checkpoint kinases. Proc Natl Acad Sci U S A 101(30):10845–10846CrossRefGoogle Scholar
  43. 53.
    Cytyc Corp. The ThinPrep system – how it works? http://www.cytyc.com/85506?prd/prepwork.html. Cited February 26, 2007
  44. 55.
    Denny L, Kuhn L, Pollack A et al (2000) Evaluation of alternative methods of cervical cancer screening for resource-poor settings. Cancer 89(4):826–833CrossRefPubMedGoogle Scholar
  45. 56.
    DeNoon D (2006) Soking boosts cervical cancer risk. According to Gunelli A. Cancer epidemiology, biomarkers & prevention 15:2141–2147. News release, American Association for Cancer ResearchGoogle Scholar
  46. 57.
    Digene. Hybrid Capture 2 Technology. http://digene.com/labs. Cited July 19, 2007
  47. 58.
    Diamics. C-map cervical cancer screening system. http://www.diamics.com/mo5.htm. Cited April 30, 2007
  48. 59.
    Donnatelle RJ, Davis LG (1997) Health: the basics. Allyn & Becon, BostonGoogle Scholar
  49. 60.
    Dunne EF, Unger ER, Stenberg M et al (2007) Prevalence of HPV infection among females in the United States. JAMA 298(8):813–819CrossRefGoogle Scholar
  50. 62.
    Eluf-Neto J, Booth M, Munoz N et al (1994) Human papillomavirus and invasive cervical cancer in Brazil. Br J Cancer 69(1):114–119CrossRefPubMedPubMedCentralGoogle Scholar
  51. 63.
    Eltoum IA, Robeson J. Impact of HPV testing, HPV vaccine development, and changing screening frequency on national Pap test volume (Projections from the National Health Interview Survey). Cancer Cytopathol. Published Online 29 January 2009 in Willey InterScience www.interscience.willey.com. Cited May 4, 2007
  52. 64.
    Epigee Women’s Health. Herpes resource. From http://www.epigee.org/guide/stds.html. Cited May 28, 2007
  53. 67.
    Eysenck HJ (1994) Synergistic interaction between psychological and physical factors in the causation of lung cancer. In: Lewis C, O’Sulivan C, Baraclough J (eds) The psychoimmunology of cancer. Oxford University Press, Oxford, pp 163–178Google Scholar
  54. 68.
    Fox SI (1999) Human physiology. WCB/McGraw-Hill, BostonGoogle Scholar
  55. 69.
    Franco EL, Schlecht NF, Saslow D (2003) The epidemiology of cervical cancer. Cancer L 9(5):348–359Google Scholar
  56. 70.
    Garcia-Hernandez E, Gonzales-Sanchez JL, Andrade-Manzano A et al (2006) Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. Cancer Gene Ther 13:592–597CrossRefPubMedGoogle Scholar
  57. 71.
    Gill G. Personal citation of CLIA*88 paragraph (f). Published on mest@cytopathology.org. Cited May 6, 2007Google Scholar
  58. 73.
    Glaxo SmithKline. Cervarix a GSK’s candidate vaccine for cervical cancer, demonstrated sustained efficacy for up to 4.5 years and broader protection against cancer causing HPV types. http://www.gsk.com/ControllerServlet. Cited July 25, 2007
  59. 74.
    Glickman J. Basic facts on HPV. Health science report. http://health-science-report.com/alotek/topics1/article3/ of January 2 2007. Cited January 2, 2007
  60. 76.
    Greenwell P, Dwek M. Biomarkers for HPV and cervical cancer: proteomics and glycomics. University of Westminster. Project design. http://wmin.ac.uk/bioscience/page-530. Cited July 5, 2007
  61. 77.
    Guccione K. Women in government issues new state policy recommendation. Women in government. http://www.judicialwatch.org/printer_6299.shtml. Cited August 5, 2007
  62. 82.
    Health & Medical News. A PAP test replacement? http://www.abc.net.au/science on April 20 2001. Cited December 8, 2006
  63. 83.
    Hildesheim A, Herrero R, Castle PE et al (2001) HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer 84(9):1219–1226CrossRefPubMedPubMedCentralGoogle Scholar
  64. 84.
    Histopathology Atlas. Histopathology of the uterine cervix – digital atlas. Frappart L, Fontaniere B, Lucas E, Sankaranaranayan R. IARC Screening Group. ISBN 92 832 2424 8. http://screenijng.iarc.fr/atlashisto. Cited September 29, 2007
  65. 85.
    Hubard RA. Human papillomavirus testing methods. Archives of pathology and laboratory medicine, August 1, 2003. From LookSmart on Internet http://findarticles.com/p/articles. Cited June 30, 2007
  66. 88.
    IARC Screening Group. Colposcopy and treatment of cervical intraepithe-lial neoplasia. Chapter 2. An introduction to cervical intraepithelial neoplasia (CIN). http://screening.iarc.fr/colpochap.php. Cited June 23, 2007
  67. 89.
    IARC Screening Group. The Bethesda system http://screening.iarc.fr/atlas-classifbethesda.php. Cited January 5, 2007
  68. 90.
    International Union Against Cancer (UICC). TNM classification of malignant tumors http://www.uicc.org/index2.php?option=com. Cited April 2, 2007
  69. 91.
    IARC Handbooks on Cancer Prevention (2005) Vol 10. Cervix cancer screening. ISBN 92 832 3010 8Google Scholar
  70. 92.
    IARC Screening Group Home Page. Cervical cancer. http://screening.iarc.fr/. Cited June 15, 2007
  71. 93.
    Idman PD. Treatment of cervical dysplasia. Advanced gynecology solutions http://www.gynalternatives.com/cervical_dysplasia_treatment.html. Cited August 2, 2007
  72. 94.
    Incidence (epidemiology) from Wikipedia. http://en.wikipedia.org/wiki/Incidence_(epidemiology). Cited September 14, 2007
  73. 95.
    Internet Health Library. Cervical cancer research. Diet & lifestyle. http://www.internethealthlibrary.com/Health_problems/Cervical%20Cancer%%20. Cited June 22, 2007
  74. 96.
    Judicial Watch. Judicial Watch uncovers three deaths relating to HPV vac-cine (Gardasil) and 1637 adverse reactions. http://judicialwatch.org/printer_6299.shtml. Cited September 2, 2007
  75. 97.
    Kodner CM, Nastraty S (2004) Management of genital warts. Am Fam Physician 70:2335–2346. http://www.aafp.org/afp/20041215/2335.htoml. Cited September 2, 2007
  76. 98.
    Kjaer SK (1998) Risk factors for cervical neoplasia in Denmark. APMIS Suppl 80:1–41PubMedGoogle Scholar
  77. 100.
    Kautsky LA (2007) Quadrivalent vaccine against human papilloma virus to prevent high-grade cervical lesions. NEJM 356(19):1915–1927CrossRefGoogle Scholar
  78. 101.
    Kolonel LH, Hankin JH et al (1981) Nutrient intakes in relation to cancer in Hawaii. Br J Cancer 44:332CrossRefPubMedPubMedCentralGoogle Scholar
  79. 102.
    Koss LG (1992) The Papanicolaou stain. Diagnostic cytology and its histopathology basis, 4th edn. Lippincott, PhiladelphiaGoogle Scholar
  80. 103.
    Kumar S. Nanolithography. In vivo optical detection of intracellular cancer biomarkers using gold nanoparticles. Spie Digital Library. http://spiedl.aip.org/getabs.servlet. Cited August 30, 2007
  81. 104.
    Lang LH. UNC researcher study new biomarker to improve screening for cervical cancer. University North Carolina News Services, October 1, 1999, No 584. http://www.unc.ed/archives/oct99. Cited September 3, 2007
  82. 106.
    List of causes of death by rate. From Wikipedia. http://en.wikipedia.org/wiki/List_of_causes_of_death_by_rate. Cited September 14, 2007
  83. 107.
    Liton SC et al (2005) Mayo clinical family health book, 3rd edn. Genetic Testing, HarperCollins, ISBN-10: 0-06-0002590-6Google Scholar
  84. 108.
    Ludwig JA, Weinstein JN (2005) Biomarkers in cancer staging, prognosis and treatment selection. Nature reviews/cancer. Nature Publishing Group 5:845–856, and http://www.nature/reviews/cancer. Cited September 14, 2007
  85. 112.
    Malinowski DP (2007) Multiple biomarkers in molecular oncology. I. Molecular diagnostics application in cervical cancer detection. Expert Rev Med Diagn 7(2):117–131CrossRefGoogle Scholar
  86. 113.
    Marcial-Toledo S, Cortez-Guzman J, Chavez L et al (2006) Screen-and treat colposcopy as public health strategy fore cervical cancer early detection in high risk population: the experience of the Centro de Estudios y Prevencion del Cancer (CEPREC) in indigenous population of Southern Mexico. J Clin Oncol, 2006 ASCO Annual meeting proceedings Part 1, Vol. 24, No. 18S (June 20 Supplement), 5012. http://www.gardasil.com. Cited January 2, 2007
  87. 114.
    Markovic N, Markovic O (2000) CAP-PAP test. US Patent 6,143,512, 20 Nov 2000Google Scholar
  88. 115.
    Markovic O, Markovic N (2003/2004) Cervical acid phosphatase: a biomarker of cervical dysplasia and a potential surrogate endpoint for colposcopy. Dis Markers 19:279–286Google Scholar
  89. 116.
    Markovic N, Markovic O, Sundeen J (2004). BioSciCon Cervical Cancer Study Group. Pap test and a new biomarker-based technology for enhancing the visibility of abnormal cells. 2004 ASCO annual meeting, New Orleans, J Clin Oncol Suppl 22(1):9561. Slide presentation available on http://www.asco.org/portal/site/ASCO/menuitem. Cited September 19, 2007
  90. 118.
    Markovic N, Markovic O (2006) The power of the biomarker for cervical cancer control. 2006 ASCO annual meeting. J Clin Oncol Suppl 24:11001(18S). http://www.asco.org/portal/site/. Cited July 7, 2007
  91. 119.
    Markovic N, Markovic O, Henderson E (2006) MarkPap digital, a new prospective for biomarker-based gynecological cytology. Ann meeting of the AACR, April 2006, Washington, DCGoogle Scholar
  92. 120.
    Markovic N, Markovic O (2007). MarkPap test and HPV vaccination. BIO international convention. 2006, innovative corridor, Boston http://72.14.209.104…/Poster/Listing.aspx. www.bioscicon/publications.html. Cited August 1, 2007
  93. 122.
    Markovic N, Markovic O (2003–2007). publications are available on the Internet at the BioSciCon web site http://www.bioscicon.com/publications.html
  94. 123.
    Maugh T, Chong J (2007) The highly tooted treatment to prevent cervical cancer may be less effective than previously thought. Article in Los Angeles Times on May 10, 2007Google Scholar
  95. 124.
    Merck & Co., Inc. Products. Gardasil [Quadrivalent HPV vaccine]. Risk for HPV. Information. From Internet http://meck.com and http://www.gardasil.com. Cited September 29, 2007
  96. 127.
    Miller K, Blumenthal P, Blanchard K (2004) Oral contraceptives and cervical cancer: critique of a recent review. Contraception 69:347–351CrossRefPubMedGoogle Scholar
  97. 128.
    Minkin MJ, Wright CV (2003) The Yale guide to women’s reproductive health. Yale University Press, New HavenGoogle Scholar
  98. 130.
    National Cancer Institute Fact Sheets. Cancer advances in focus. Cervical cancer (posted October 30 2006). Retrieved from Internet http://www.cancer.gov/aboutnci/cancer-advances-in-focus/cervical. Cited May 31, 2007
  99. 132.
    National Cancer Institute. Antioxidants and cancer prevention. Fact Sheet. http://www.cancer.gov/cancertopics/factsheet/antioxidantsprevention. Cited June 28, 2007
  100. 133.
    National Cancer Institute. Notice for contract solicitations. NOT-CA-02-011. Defining and validating biomarkers of risk for progressive cervical cancer. http://grants.nih.gov/guide/notice-files/NOT-CA-02-011.html. Cited September 2, 2007
  101. 135.
    National Cancer Institute. Surveilance Epidemiology and End Results (SEER), cervical cancer, http://seer.cancer.gov/statfacts/html/cervix.htm. Cited September 12, 2007
  102. 136.
    NIH, NCI, FactSheet. Oral contraceptives and cancer risk: Q&A. http://www.cancer.gov/cancertopics/faxtsheer/Risk/oral-contraceptives. Cited June 23, 2007
  103. 138.
    NIH Consensus Conference on Cervical Cancer (1966) NIH consensus statement online 1–3: 43(1):1–38Google Scholar
  104. 139.
    NIH, NCI, FactSheet. Antioxidants and cancer prevention: Fact Sheet. http://cancer.gov?cancertopics/factsheet/antioxidantsprevention, of June 22 2007. Cited September 12, 2007
  105. 140.
    NIH Consensus Statement No. 102. Cervical cancer. NIH Consent/Statement 1996 April 1–3; 14(10):1–38Google Scholar
  106. 141.
    Nisl J. Colposcopy and cervical biopsy. WebMD. Cancer Health Center. F http://www.webmd.com/cancer/Colposcopy-and-Cervical-Biopsy. Cited September 12, 2007
  107. 143.
    Obermair A, Bancher-Todesca D, Bilgi S et al (1997) Correlation of vascular endothelial growth factor expression and microvessel density in cervical intraepithelial neoplasia. J Natl Cancer Inst 89:1212–1217CrossRefPubMedGoogle Scholar
  108. 144.
    Oberman E, Went F, Zimpfer A et al (2005) Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma; a tissue microarray and clinico-pathological analysis. BMC Cancer 5:162–172CrossRefGoogle Scholar
  109. 145.
    Orr JW Jr, Wilson K, Bodiford C et al (1985) Corpus and cervix cancer: a nutritional comparison. Am J Obstet Gynecol 153(7):775–779CrossRefPubMedGoogle Scholar
  110. 148.
    Public Law US 102–139, Title 1, Section 101, 105 Statute 742 (1991)Google Scholar
  111. 152.
    Reesink-Peters N, Wisman GBA, Jeronimo C et al (2004) Detecting cervical by quantitative promoter hypermethylation assay on cervical scrapings: a feasibility study. Mol Cancer Res 2:289–295PubMedGoogle Scholar
  112. 153.
    Ruffin MT, Ogaily MS, Johnston CM et al (1995) Surrogate endpoint biomarkers for cervical cancer chemoprevention. J Cell Biochem Suppl 23:113–124CrossRefPubMedGoogle Scholar
  113. 154.
    Sankaranarayanan R et al (2005) A cluster randomized controlled trial of visual, cytology and human papilloma virus screening for cancer of the cervix in rural India. Int J Cancer 116(4):617–623CrossRefPubMedGoogle Scholar
  114. 155.
    Sankaranarayanan R et al (2007) Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomized trial. Lancet 370:398–406CrossRefPubMedGoogle Scholar
  115. 156.
    Scanlan RA. Nitrosamines and cancer. The Linus Pauling Institute. Oregon University. http://lpi.oregonstate.edu/f-w00/nitrosamine.html. Cited September 6, 2007
  116. 160.
    Shields TS, Brinton LA, Wang SS et al (2004) A case-control study of risk factors got invasive cervical cancer among U.S. women exposed to oncogenic types of human papilloma virus. Cancer Epidemiol Biomark Prev 3(10):1574–1582Google Scholar
  117. 161.
    Smith JS, Lindsay L, Hoots B et al (2007) Human papilloma virus type distribution in invasive cervical cancer and high-grade cervical lesions. A metaanalysis update. Int J Cancer 121:621–632CrossRefPubMedGoogle Scholar
  118. 162.
    Solomon D, Davey D, Kurman R et al (2002) The 2001 Bethesda system. Terminology for reporting results of cervical cytology. JAMA 287(16):2114–2119CrossRefPubMedGoogle Scholar
  119. 163.
    Solomon D, Schiffman M (2001) Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial (ALTS). J Natl Cancer Inst 93(12):293–299, and Response in J Natl Cancer Inst 93(12):251–252Google Scholar
  120. 164.
    Suba EJ, Donnelly AD, Furia L et al (2007) Cervical cancer prevention for all the world’s women: genuine promise resides in skilled quality management rather than novel screening approaches. Diagn Cytopathol 35(3):187–191CrossRefPubMedGoogle Scholar
  121. 165.
    Tang YW, Stratton CW. Advanced techniques in Diagnostic Microbiology. Amazon. http://www.amazon.com/exec/obidos/. Cited September 4, 2007
  122. 166.
    Takahashi Shoji. Diagnosis and treatment of cervical cancer. Office of Technology Development. GTU, Washington, DC. http://otl.georgetown.edu/industry/inventions. Cited September 24, 2007
  123. 168.
    Thomas DB, Ray RM, Koetsawang A et al (2001) Human papillomaviruses and cervical cancer in Bangkok. I. Risk factors for invasive cervical carcinomas with human papillomavirus types 16 and 18 DNA. Am J Epidemiol 153(8):723–731CrossRefPubMedGoogle Scholar
  124. 169.
    Thomson FE, Patterson BH, Weinstein SJ et al (2002) Serum selenium and the risk of cervical cancer among women in the United States. Cancer Cause Control 13(6):517–526CrossRefGoogle Scholar
  125. 170.
    ThermoShandon. Thermo scientific. Anatomic pathology. Products. http://www.thermo.com. Cited September 29, 2007
  126. 171.
    TNM Classification of Malignant Tumors. From Wikipedia on Internet, http://en.wikipedia.org/wiki/TNM
  127. 172.
    TriPath Imaging Home. http://www.tripathimaging.com
  128. 173.
  129. 174.
    Velema JP, Ferrera A, Figueroa M et al (2002) Burning wood in the kitchen increases the risk of cervical neoplasia in HPV-infected women in Honduras. Int J Cancer 97(4):536–541CrossRefPubMedGoogle Scholar
  130. 175.
    World Health Organization (1947) Constitution of the WHO. Chronicles of the WHO, GenevaGoogle Scholar
  131. 176.
    WHO HIV/AIDS Guidelines. http://who.int/hiv/pub/guideline/en. Cited on September 29, 2007
  132. 177.
    WHO Department of Vaccine Research and Biologicals. Human HPV and HPV vaccines: technical information for policy makers and health professionals. WHO Press 2007. Cited on September 6, 2007Google Scholar
  133. 178.
    Women in US Government. Challenge to eliminate cervical cancer. Policy Recommendation. http://www.womeningovernment.org/prevention. Cited on September 29, 2007
  134. 179.
    Wikipedia, the free encyclopedia. Epidemiology. http://en.wikipedia/wiki/Epidemiology. Cited August 27, 2007
  135. 180.
    Wikipedia. Histology http://en.wikipedia.org/wiki/Histology. Cited September 12, 2007
  136. 181.
    Wikipedia, the free encyclopedia. Radiation therapy. http://en.wikipedia.org/wiki/Raiationtherapy. Cited September 7, 2007
  137. 182.
    Wright VC (1984) Carbon dioxide laser surgery for cervical intraepithelial neoplasia. Laser Surg Med 4(2):145–152CrossRefGoogle Scholar
  138. 183.
    Wright T et al (2002) ASCCP 2001 consensus guidelines for the management of women with cervical cytological abnormalities. JAMA 287(16):2120–2129CrossRefPubMedGoogle Scholar
  139. 184.
    www.nccn.org NCCN clinical practice guidelines in oncology. Cervical cancer screening, V1.2008. Cited September 8, 2007
  140. 185.
  141. 186.
    Yoon SK, Lim NK, Ha SA, et al (2004) The human cervical cancer oncogene protein is a biomarker for human hepato-cellular carcinoma. Cancer Res 64:5434–5441. http://cancerres.aacrjournals.org/cgi/content/abstract/64/15/5434. Cited July 5, 2007
  142. 187.
    Youngerman-Cole S et al Pelvic examination. WebMD. Women’s health http://women.webmd.com/Women-MedicalReference/Pelvic-Examination. Cited June 28, 2007
  143. 189.
    Zenillman JM (2001) Chlamydia and cervical cancer: a real association? JAMA 285:81–83CrossRefGoogle Scholar
  144. 190.
    de Zelmanowicz A, Hildesheim A (2004) Family history of cancer as a risk factor for cervical carcinoma: a review of the literature. Papillomavirus Rep 15(3):113–120CrossRefGoogle Scholar
  145. 191.
    Ziegler RG (1986) Epidemiologic studies of vitamins and cancer of the lung, esophagus, and cervix. Adv Exp Med Biol 206, ISSN 0065–2598 Journal Code:2LUGoogle Scholar
  146. 192.
    Ziegler RG, Jones AC, Rosenthal JF, et al (1991) Diet and the risk of in situ cervical cancer among white women in the United States. Cancer Cause Control 2(1):17–29, ISSN 0957–5243Google Scholar
  147. 193.
    Zuna RE, Allen RA, Moore WE, et al (2004). Comparison of human papilloma virus genotypes in high-grade squamous intraepithelial lesions and invasive cervical carcinoma: evidence for differences in biologic potential of precursor lesions. Mod Pathol 17:1314–1322 (presented at the 92nd annual meeting of the US and Canadian Academy of Pathology, Washington, DC, March 2003)Google Scholar
  148. 212.
  149. 220.
    www.bioscicon.com/publications html. Accessed June 2015

Copyright information

© Springer Science+Business Media B.V. 2016

Authors and Affiliations

  • Nenad Markovic
    • 1
  • Olivera Markovic
    • 2
  1. 1.Global Academy for Women’s Health, Inc.Medical Center DriveRockvilleUSA
  2. 2.Education Global Academy for Women’s Health, Inc.RockvilleUSA

Personalised recommendations